Long-term oral effects in patients treated with radiochemotherapy for head and neck cancer

Supportive Care in Cancer

Volumn 20, Issue 11, 2012, Pages 2903-2911

  Da Silva Deboni, Aline Lima ^a   Giordani, Adelmo José ^a   Lopes, Nilza Nelly Fontana ^a   Dias, Rodrigo Souza ^a   Segreto, Roberto Araujo ^a   Jensen, Siri Beier ^b   Segreto, Helena Regina Comodo ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Chemotherapy; Head and neck cancer; Late effect; Oral complication; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER PATIENT; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COBALT TELETHERAPY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; MALE; MEDICAL RECORD REVIEW; MORBIDITY; MOUTH DISEASE; ORAL MUCOSAL DISEASE; PRIORITY JOURNAL; RADIATION DOSE; RISK FACTOR; SALIVA FLOW RATE; SALIVARY GLAND DISEASE; SALIVARY GLAND EXAMINATION; SALIVARY GLAND FUNCTION; SALIVATION; SIALOMETRY; XEROSTOMIA;

CHEMORADIOTHERAPY; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MOUTH MUCOSA; RISK FACTORS; SALIVA; SALIVARY GLANDS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; XEROSTOMIA;

EID: 84868500272     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1418-7     Document Type: Article

References (45)

1. Shah JP, Gil Z (2009) Current concepts in management of oral cancer - surgery. Oral Oncol 45:394-401
2. Gallegos-Hernández JF (2006) Head and neck cancer. Risk factors and prevention. Cir Cir 74(4):287-93
3. McMahon S, Chen AY (2003) Head and neck cancer. Cancer Metastasis Rev 22:21-24
4. Döbrõssy L (2005) Epidemiology of head and neck cancer: magnitude of the problem. Cancer Metastasis Rev 24:9-17
5. Chua DTT, Tian Y, Wei WI (2007) Late oral complications following radiotherapy for head and neck cancers. Expert Rev Anticancer Ther 7(9):1215-1224
6. Zackrisson B, Mercke C, Strander H et al (2003) A systematic overview of radiation therapy effects in head and neck cancer. Acta Oncol 42(5):443-461
7. Al-Sarraf M, Pajak TF, Byhardt RW et al (1997) Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24. Int J Radiat Oncol Biol Phys 37(4):777-782
8. Newlin HE, Amdur RJ, Riggs CE et al (2010) Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer. Cancer 116:4533-4540
9. Bentzen SM, Rosenthal DI,Weymuller EA, Trotti A (2007) Increasing toxicity in nonoperative head and neck cancer treatment: investigations and interventions. Int J Radiat Oncol Biol Phys 69(2 Suppl): S79-S82
10. Pignon JP, Maître AL, Bourhis J et al (2007) Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 69(2 Suppl):S112-S114
11. Langendijk JA (2007) New developments in radiotherapy of head and neck cancer: higher precision with less patient discomfort? Radiother Oncol 85:1-6
12. Trotti A (2000) Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys 47(1):1-12
13. KawashimaM(2004) Chemoradiotherapy for head and neck cancer: current status and perspectives. Int J Clin Oncol 9:421-434
14. Dirix P, Abbeel S, Vanstraelen B et al (2009) Dysphagia after chemoradiotherapy for head-and-neck squamous cell carcinoma: dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 75(2):385-392
15. Perlmutter MA, Johnson JT, Snyderman CH et al (2002) Functional outcomes after treatment of squamous cell carcinoma of the base of the tongue. Arch Otolaryngol Head Neck Surg 128:887-891
16. Eisbruch A, Rhodus RD et al (2003) The prevention and treatment of radiotherapy-induced xerostomia. Semin Radiat Oncol 13 (3):302-308
17. Jensen SB, Pedersen AM, Reibel J, Nauntofte B (2003) Xerostomia and hypofunction of the salivary glands in cancer therapy. Support Care Cancer 11:207-225
18. Saad ED, Hoff PM, Carnelós RP et al (2002) Critérios Comuns de Toxicidade do Instituto Nacional de Câncer dos Estados Unidos (Common toxicity criteria of the National Cancer Institute). Rev Bras Cancerol 48(1):63-96
19. Cancer Therapy Evaluation Program (1999) Common Toxicity Criteria, Version 2.0. http://ctep.cancer.gov/protocoldevelopment/electronic-applications/ docs/ctcv20-4-30-992.pdf. Accessed 20 Jan 2010
20. Eisbrush A, Rhodus N, Rosenthal D et al (2003) How should we measure and report radiotherapy-induced xerostomia? Semin Radiat Oncol 13(3):226-234
21. Radiation Therapy Oncology Group (1999) A phase III study to test the efficacy of the prophylatic use of oral pilocarpine to reduce hyposalivation and mucositis associated with curative radiation therapy in head and neck cancer patients. RTOG97-09. Philadelphia, PA: Radiation Therapy Oncology Group. www.rtog.org/members/protocols/97-09/97-09.pdf. Accessed 20 Jan 2010
22. Navazesh M, Christensen CM (1982) A comparison of whole mouth resting and stimulated salivary measurement procedures. J Dent Res 61(10):1158-62
23. Adelstein DJ (2007) Concurrent chemoradiotherapy in the management of squamous cell cancer of the oropharynx: current standards and future directions. Int J Radiat Oncol Biol Phys 69(2 Suppl): S37-S39
24. Furness S, Glenny AM, Worthington HVet al (2010) Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database of Systematic Reviews, 9: CD006386
25. Stone HB, Coleman CN, Anscher MS, McBride WH (2003) Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol 4:529-536
26. Givens DJ, Karnell LH, Gupta AK et al (2009) Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 135 (12):1209-1217
27. Withers HR, Peters LJ, Taylor JMG (1995) Late normal tissue sequelae from radiation therapy for carcinoma of the tonsil: patterns of fractionation study of radiobiology. Int J Radiat Oncol Biol Phys 33(3):563-568
28. Citrin D, Mansueti J, Likhacheva A (2009) Long-term outcomes and toxicity of concurrent paclitaxel and radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 74 (4):1040-1046
29. Chen AM, Li BQ, Jennelle RLS et al (2010) Late esophageal toxicity after radiation therapy for head and neck cancer. Head Neck 32:178-183
30. Power DA (2005) Late effects of radiotherapy: how to assess and improve outcomes. Br J Radiol 78:150-152
31. Cooper JS, Fu K, Marks J, Silverman S (1995) Late effects of radiation therapy in the head and neck region. Int J Radiation Oncology Biol Phys 31(5):1141-1164
32. Vissink A, Jansma J, Spijkervet FKL (2003) Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 14(3):199-212
33. Olmi P, Crispino S, Fallai C et al (2006) Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy - a multicenter randomized trial. Int J Radiat Oncol Biol Phys 55(1):78-92
34. Machtay M, Moughan J, Trotti A et al (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26:3582-3589
35. Fischer DJ, Epstein JB (2008) Management of patients who have undergone head and neck cancer therapy. Dent Clin N Am 52:39-60
36. Epstein JB, Stevensen-Moore P (2001) Periodontal disease and periodontal management in patients with cancer. Oral Oncol 37:613-619
37. Eisbruch A, Kim HM, Terrel JE et al (2001) Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 50(3):695-704
38. Sonis ST, Fey EG (2002) Oral complications of cancer therapy. Oncology 16(5):680-686
39. Yeh SA, Tang Y, Lui CC et al (2005) Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 62 (3):672-679
40. Fu KK, Pajak TF, Marcial VA et al (1995) Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13. Int J Radiat Oncol Biol Phys 32(3):577-588
41. Sreebny LM, Valdini A (2006) Xerostomia. Part I: relationship to other oral symptoms and salivary gland hypofunction. Oral Surg Oral Med Oral Pathol 66(4):451-458
42. Guchelaar HJ, Vermes A, Meerwaldt JH (1997) Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment. Support Care Cancer 5:281-288
43. Kaplan I, Zuk-Paz L,Wolff A (2008) Association between salivary flow rates, oral symptoms, and oral mucosal status. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106:235-41
44. Jensen SB et al (2010) A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer 18 (8):1061-79
45. Rose-Ped AM, Bellm LA, Epstein JB et al (2002) Complications of radiation therapy for head and neck cancers. Cancer Nurs 25 (6):461-465